Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Christophe Le TourneauYungan TaoCarlos Alberto Gomez RocaValerie CristinaEdith BorcomanEric DeutschRastislav BahledaValentin CalugaruAnouchka ModestoElisabeth RouitsKathrin GollmerGregoire VuagniauxPhilippa CromptonClaudio ZannaSergio SzyldergemajnJean-Pierre DelordJean BourhisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The RP2D of Debio 1143 is 200 mg/day for 14 days, every 3 weeks, when combined with concomitant high-dose cisplatin chemoradiotherapy in LA-SCCHN. Debio 1143 addition to chemoradiotherapy was safe and manageable. Preliminary efficacy is encouraging and supports further development.
Keyphrases
- locally advanced
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- high dose
- phase ii study
- radiation therapy
- oxidative stress
- low dose
- clinical trial
- endoplasmic reticulum stress
- study protocol
- phase iii
- lymph node metastasis
- cell death
- stem cell transplantation
- phase ii
- gestational age
- randomized controlled trial